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Summary
The industrial production of fine chemicals, feed and food ingredients, pharmaceuti-
cals, agrochemicals and their respective intermediates relies on an increasing application
of biocatalysis, i.e. on enzyme or whole-cell catalyzed conversions of molecules. Simple
procedures for discovery, cloning and over-expression as well as fast growth favour fungi,
yeasts and especially bacteria as sources of biocatalysts. Higher eukaryotes also harbour
an almost unlimited number of potential biocatalysts, although to date the limited supply
of enzymes, the high heterogeneity of enzyme preparations and the hazard of infectious
contaminants keep some interesting candidates out of reach for industrial bioprocesses. In
the past only a few animal and plant enzymes from agricultural waste materials were em-
ployed in food processing. The use of bacterial expression strains or non-conventional
yeasts for the heterologous production of efficient eukaryotic enzymes can overcome the
bottleneck in enzyme supply and provide sufficient amounts of homogenous enzyme pre-
parations for reliable and economically feasible applications at large scale. Ideal enzymatic
processes represent an environmentally friendly, »near-to-completion« conversion of (mostly
non-natural) substrates to pure products. Recent developments demonstrate the commer-
cial feasibility of large-scale biocatalytic processes employing enzymes from higher eu-
karyotes (e.g. plants, animals) and also their usefulness in some small-scale industrial ap-
plications.
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Microorganisms and their enzymes are widely ex-
ploited in biocatalysis to produce a broad spectrum of
fine chemicals, pharmaceuticals and their building blocks,
as well as commodity and agrochemicals (1–4). The pre-
ferred use of enzymes from bacteria and fungi in com-
petitive large-scale bioprocesses stems from their simple
and quick genetic manipulation (5) and also the simple
access to large amounts of native enzymes. For compari-
son, higher eukaryotes provide interesting enzymes (6–8),
but they usually need to be isolated and purified or
cloned and over-expressed in suitable hosts in order to
obtain sufficient quantities for biocatalytic applications.
In the past years, the use of synthetic host-adopted genes
and codon-optimized Escherichia coli strains and the de-
velopment of highly successful eukaryotic expression
systems, such as the methylotrophic yeasts Pichia pasto-
ris and Hansenula polymorpha, have enabled the produc-
tion of large quantities of eukaryotic enzymes within a
short time (9).
An increasing experience in molecular modelling
(10,11), which rationalizes molecule and biocatalyst en-
gineering, as well as recent progress in high-throughput
technologies for the expression and engineering of eu-
karyotic proteins provide great potential to extend in-
dustrial applications of eukaryotic enzymes (12). Directed
evolution of enzymes in the test tube by repeated cycles
of random mutagenesis or recombination followed by
screening and selection provides a powerful tool if
structural or mechanistic information is not available
and if efficient screening technology exists (13). In addi-
tion, this technology gives access to improved enzymes
due to mutations that could not be predicted based on
knowledge from static enzyme models.
Enzymes from higher eukaryotes have been tradi-
tionally used in the food industry, for example, as food
additives, in fruit processing, in wine brewing and as
pharmaceutical additives. Examples include the extensive
use of papain, bromelain, chymosin, ficin, lipoxygenase
or pepsin (14). However, most of these processes were
already developed in the 1980s (15–17) and therefore
cannot be considered as recent applications, although the
products are still widely used.
Oxidoreductases (E.C. 1), hydrolases (E.C. 3), lyases
(E.C. 4) and isomerases (E.C. 5) provide the vast major-
ity of examples of higher eukaryotic enzymes for indus-
trial applications; there are no commercial processes re-
ported for plant or animal enzymes from other catalytic
groups. In this review, the main focus is on implemented
biocatalytic applications of eukaryotic enzymes in in-
dustrial processes for the production of fine chemicals,
as well as some recent promising developments at pilot
scale and for the preparative synthesis of compounds
for industrial drug development processes.
Production of Fine Chemicals and Metabolites
with E.C. 1 – Oxidoreductases
Mammalian cytochrome P450
Mammalian cytochrome P450 (CYP) monooxygena-
ses comprise a superfamily of hemoproteins with extra-
ordinary catalytic versatility. They catalyze the metabo-
lism of a wide variety of endogenous and exogenous
compounds including environmental contaminants, hor-
mones, therapeutic drugs and (pro)carcinogens (18–20).
The human CYP enzyme system is divided into two
large subgroups, the steroidogenic and xenobiotic enzy-
mes. Some extrahepatic P450s have roles in the mainte-
nance of homeostasis and signal transduction. Steroido-
genic P450s synthesize steroids and other substances
necessary for the maintenance of cell wall integrity and
cellular differentiation. The majority of enzymes of the
human xenobiotic group are expressed in liver micro-
somes. They perform a number of physiological func-
tions but their primary role is in the metabolism of xeno-
biotics. A large number of potential drug candidates fail
in later stages of drug development because they are
readily degraded or because they interfere with the me-
tabolism of other therapeutics by human cytochrome P450
(CYP) isozymes. An early assessment of drug/drug in-
teractions and isozyme-specific CYP450 induction or in-
hibition is an essential part of the modern drug discov-
ery process (20).
Among these CYP isozymes, the CYP3A enzyme fa-
mily is responsible for the hepatic metabolism of approxi-
mately 60 % of currently available pharmaceutical agents
(such as Mephenytoin®, Nevirapine®, Nifedipine®, Nicar-
dipine®, Cyclophosphamide®, Clotrimazole®, Erythromy-
cin® and Fluconazole®) (21,22). About 25 % of all drugs
used today are substrates for the CYP2D6 isozyme (23)
and many others inhibit or induce its activity. Approxi-
mately 15 % of all drugs used today are metabolized by
the CYP1A2 isozyme (23).
Industrial application of human P450s evolves into
two different directions: (i) the production of active
pharmaceutical intermediates, and (ii) the simple and
fast production of metabolites in mg-scale for drug de-
velopment.
Human cytochrome P450s have been expressed in
different systems such as mammalian cells (24,25), insect
cells (26), yeasts (27–29) and bacteria such as Escherichia
coli (30,31). E. coli expression systems have the advan-
tages of being easier and less expensive to operate and
of yielding higher quantities of recombinant proteins.
Folding and solubility problems are usually solved by
synthesis of optimized genes and N-terminal fusions
with other protein sequences that allow correct targeting
or increase protein solubility. Dramatic improvement in
the levels of reconstitution of activity of human CYP450
in Escherichia coli was obtained by coexpression of P450
reductase (32,33). Recently, a human mitochondrial cyto-
chrome P450 (P450 aldosterone synthase) was function-
ally expressed in the fission yeast Schizosaccharomyces
pombe. No co-expression of P450 reductase was needed
for efficient substrate conversion by intact fission yeast
cells. Expression was much higher in fission yeast mi-
crosomes than in Saccharomyces cerevisiae and the trans-
formed yeast showed inducible activity for the in vivo
conversion of considerable amounts of 11-deoxycortisol
to cortisol. Furthermore, 11-deoxycorticosterone could be
converted almost entirely to corticosterone, with small
amounts of 18-hydroxycorticosterone and aldosterone as
by-products (29). This study can be regarded as a signif-
icant step towards simple and efficient over-expression
and characterization of human P450s and represents
considerable progress concerning their possible applica-
tions in fermentative production processes.
The co-expression of human CYP3A4 and human
NADPH-cytochrome P450 oxidoreductase in insect cells
(aided by baculoviral infection) was reported by a group
of the Merck Research Laboratories in 2000 (34). The aim
was to establish a platform for both the production and
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subsequent purification of milligram quantities of P450-
generated metabolites. According to the authors, the
large-scale production (which is still in the scale of sev-
eral milligrams) of metabolites derived from the standard
substrates testosterone, diazepam and diclofenac was
achieved and could be scaled up further if necessary.
Shaw et al. (35) demonstrated the development of
ready-to-use premixed human enzyme preparations, con-
sisting of CYP3A4, NADPH-P450 reductase, cytochrome
b5 and liposomes, for the large-scale screening of novel
P450 substrates or inhibitors. The formulation allows for
repeated freeze-thaw cycles as well as prolonged storage
time at 4 or –80 °C, without significant loss of activity
on the model substrate testosterone. The striking advan-
tage of such a system is the ability to perform large
numbers of P450 assays using purified components in a
reliable fashion (35).
BioCatalytics (Pasadena, California) is commercial-
izing a comprehensive set of ready-to-use liver enzymes,
which were expressed in E. coli. This provides all six ma-
jor human liver cytochromes in a kit for simple synthe-
sis of metabolites.
There is a requirement of milligram amounts of
P450-generated metabolite(s) for toxicological evaluation
and pharmacokinetic studies in many situations during
drug discovery and development (34).
Glycolate oxidase
Glycolate oxidase is a peroxisomal oxidase that has
been isolated from many green plants and mammals, in-
cluding spinach leaves, pea, pumpkin, cucumber as well
as pig liver, rats and humans. An investigation of gly-
colate oxidase production and substrate specificity to gly-
colic acid indicated that the enzyme from spinach leaves
produced the highest yields and specific activities in terms
of glyoxylic acid production (36). The spinach glycolate
oxidase can be generally used for the oxidation of hy-
droxy carboxylic acids and it was isolated as a catalyti-
cally active tetramer or octamer made up of identical
40-kDa subunits. The crystal structure revealed that the
subunits form an eight-stranded alpha/beta barrel (37).
The biocatalytic oxidation was done in the presence of
oxygen and ethylenediamine (EDA), using glycolate
oxidase and catalase. These oxidations produced both
high yields (>99 %) and high conversions (100 %), re-
sulting in few undesirable by-products (36) (Fig. 1).
The efficiencies of the catalases from cattle liver and
Aspergillus sp. for glyoxylic acid production were com-
pared. This revealed that the fungal enzyme was supe-
rior. The technical feasibility of a biocatalytic process for
the production of glyoxylic acid was demonstrated by
the preparation of 0.50 kg of the acid in a series of 2.0-L
batch reactions with 100 % conversion. However, in this
process, the biocatalyst was not stable and could not be
recovered for subsequent reuse (36).
To make the enzyme more stable, the glycolate oxi-
dase isolated from spinach and the catalase from yeast
were immobilized on oxirane acrylic beads. Product yields
were 93–100 % after 10 batch reactions under the condi-
tions of 200–250 mM substrate concentration, 1.05–1.33
EDA/glycolic acid molar ratios and 0.58 MPa oxygen
pressure (38).
Nevertheless, purified enzymes from spinach leaves
are too expensive and not very suitable for stable en-
zyme preparations in industrial applications. Therefore
the spinach glycolate oxidase gene has been cloned and
over-expressed in Escherichia coli (39,40), Saccharomyces
cerevisiae (41) and Pichia pastoris (42). When produced in
fermentors, more than 250 units of recombinant enzyme
per gram of cells (Pichia pastoris, wet weight) were pro-
duced, which represents roughly 20–30 % of the soluble
cell protein. Using permeabilized recombinant Pichia cells
as biocatalyst, the biotransformation was carried out to
completion with 98 % yield of glyoxylic acid after 4.5 h.
This was the first example of expression of a plant gene
in P. pastoris and, more significantly, the first example of
engineering P. pastoris as a whole cell catalyst for the ex-
plicit purpose of commercial bioprocess development (42).
The co-expression of spinach glycolate oxidase and
catalase T from Saccharomyces cerevisiae in Pichia pastoris
has been investigated in order to enable the efficient si-
multaneous production of multiple enzymes, and after-
wards to develop this system for commercial bioproces-
ses (43). The Pichia pastoris double transformant was used
for glyoxylate production and also produced high yields
of glyoxylic acid (90 %) and low amounts of by-prod-
ucts (43).































Fig. 1. Biocatalytic oxidation of glycolic acid
Adam et al. reported another commercially interest-
ing process employing this oxidase. Racemic 2-hydroxy
acids were enzymatically resolved into chiral hydroxy
acids with spinach glycolate oxidase and D-lactate de-
hydrogenase (44–46). Optically active 2-hydroxy acids are
important building blocks for the asymmetric synthesis
of glycols, halo esters and epoxides. The novel enzyma-
tic transformation revealed that the biocatalytic produc-
tion of a broad variety of (R)-hydroxy acids leads to a
high degree of enantioselectivity by preferential oxida-
tion, with glycolate oxidase, of (S)-hydroxy acids to
2-oxo acids in racemic mixtures. Following enzymatic oxi-
dation, D-lactate dehydrogenase (LDH) was added to-
gether with NADH for enantioselective reduction of the
2-oxo acid to the corresponding (R)-2-hydroxy acid. The
co-substrate NADH was recycled by the formate dehy-
drogenase (FDH) system (45) (Fig. 2). (R)-2-hydroxy acid
was produced with an excellent enantiomeric excess
(e.e.) value (>99 %, R=Et; 67 %, R=n-Bu) and high yields
(100 %) (46).
Dehydrogenase
Due to their strong capability to convert carbonyl
groups to optically pure alcohols, dehydrogenases became
very important catalysts for organic syntheses. Many
developments were focused on finding suitable biocata-
lysts with expected stereoselectivity followed by the de-
sign of commercial methods for industrial use. At large
scale, whole cell reactions were preferentially performed
because whole cells already contain the nicotinamide co-
factors (NAD(P)+/NAD(P)H) and the corresponding re-
cycling systems that are essential for commercially via-
ble biocatalytic processes (47–49). On the other hand, the
use of isolated dehydrogenases also has advantages as,
for example, in the elimination of competition with re-
ductases with different stereoselectivities or avoidance of
metabolism of substrates and products, a phenomenon
that results in lower yields and higher production of
by-products (50,51). Many important dehydrogenases ori-
ginate from microbial sources like Sulfolobus solfataricus
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
yeast alcohol dehydrogenase (YADH), Candida boidinii
formate dehydrogenase (FDH) and Escherichia coli phe-
nylalanine dehydrogenase (PDH). Bovine liver glutamate
dehydrogenase (GDH) and horse liver alcohol dehydro-
genase (HLADH) are examples from higher eukaryotes.
Bovine GDH reversibly catalyzes the reductive ami-
nation of -ketoglutarate to L-glutamate using NADH as
cofactor. The crystal structure of this homohexameric
mitochondrial enzyme has been solved at 2.8 Å resolu-
tion and some more detailed mechanisms have been de-
monstrated (52). Bovine GDH has mainly been applied
for the synthesis of L-6-hydroxynorleucine, which is a
chiral intermediate for the synthesis of Omapatrilat®
(Fig. 3), an antihypertensive drug acting as an angioten-
sin-converting enzyme (ACE) and neutral endopeptidase
inhibitor (53,54).
L-6-hydroxynorleucine is also an intermediate for the
synthesis of C-7 substituted azepinones, which are po-
tential intermediates for the synthesis of other antihy-
pertensive metalloprotease inhibitors (55). An enzymatic
method using bovine liver glutamate dehydrogenase was
developed based on the conversion of 2-keto-6-hydroxy-
hexanoic acid (synthesized by a chemical method) to
L-6-hydroxynorleucine by reductive amination (Fig. 4,
Route 1). NADH was regenerated by glucose dehydro-
genase from Bacillus sp. To avoid the necessity of the
chemical synthesis of the ketoacid from the carboxylic
acid, an alternative route with a theoretical yield of 100
% was constructed to prepare the ketoacid directly from
racemic 6-hydroxynorleucine with porcine kidney or
Trigonopsis variabilis D-amino acid oxidase and catalase,
followed by the same reductive process from bovine li-
ver GDH (53) (Fig. 4, Route 2). One method (Route 1)
used 100 g/L of substrate for the preparative reaction
and was completed in about 3 h with 92 % yield and
greater than 99 % e.e. for L-6-hydroxynorleucine in the
bovine liver GDH catalysed step.


































Fig. 3. Structure of Omapatrilat®
The second method (Route 2) (Fig. 4) also gave good
results: after the oxidation step, the mixture of 2-keto-6-
hydroxy hexanoic acid and L-6-hydroxynorleucine was
entirely converted into L-6-hydroxynorleucine with 97 %
yields from racemic 6-hydroxynorleucine and >98 % e.e.
for L-6-hydroxynorleucine (53).
Production of Fine Chemicals with E.C. 3 –
Hydrolases
Esterase and lipase
Lipases, esterases and proteases are just some of the
major representatives of the vast class of hydrolases.
Due to their broad substrate specificity, they are mainly
used for the resolution of different racemic compounds
to obtain chiral products. However, in the best case only
50 % of the substrate can be converted to the desired en-
antiomer by hydrolytic cleavage unless a de-racemiza-
tion process is applied. Hydrolases are widely distributed
in microorganisms, plants and mammals. From animals
a variety of tissue-specific lipases and esterases have been
isolated (56). During the last few years much attention
has been paid to the use of enzymes from microbial sour-
ces due to their easily available gene expression technol-
ogies and scale-up means (57). Also, high productivity
of microbial hosts for native secreted enzymes and high
stability of many of these enzymes favoured the selec-


















































Fig. 4. Enzymatic synthesis of L-6-hydroxynorleucine
tion of microbial hydrolases as candidates for industrial
application. However, there are many reactions for com-
mercial products carried out by hydrolases (mainly li-
pases, esterases and proteases) from higher eukaryotes.
In particular, porcine pancreatic lipase (PPL) and pig li-
ver esterase (PLE) have been widely used for produc-
tion of chiral compounds.
Porcine pancreatic lipase is the cheapest and one of
the most widely used lipases for kinetic resolution of
non-natural substrates (58). In particular, it was applied
for the resolution of glycidyl esters, which are converted
to central chiral building blocks for the production of
enantiopure pharmaceuticals (59). A process based on hy-
drolysis of racemic glycidylbutyrate with porcine pan-
creatic lipase was developed by Ladner and Whitesides
(60). The 89 % theoretical yield and 92 % e.e. for the
products make its industrial use feasible (Fig. 5). It was
finally developed by Andeno-DSM and used for the pro-
duction of (R)-glycidol on a multi-ton scale (61).
A further well-known industrial application of PPL
is the kinetic resolution of 2,3-epoxy-1-tridecanol (Fig. 6)
by selective acylation. The unconverted (2R,3S)-2,3-ep-
oxy-1-tridecanol was isolated with 27 % yield and 99 %
e.e. and used to synthesize the moth pheromone Dispar-
lur® (62).
There are also lab-scale investigations of PPL-mediat-
ed resolution that show interesting perspectives (63–65).
The enzymatic resolution of N-Boc-piperidine-2-ethanol
can be achieved by the use of Pseudomonas cepacia lipase
(Lipase PS) and porcine pancreatic lipase, respectively,
exploiting their opposite enantioselectivities. Thus, both
enantiomers of N-Boc-piperidine-2-ethanol can be ob-
tained by lipase technology. A gram scale availability of
(R)-enantiomer by lipase PS (90 % e.e.) and (S)-enantio-
mer by PPL (95 % e.e.) extends their synthetic applica-
tion to provide general access to enantiopure piperidine
alkaloids (66).
Pig liver esterase (PLE) plays a crucial role in the
enantioselective hydrolysis of prochiral or racemic esters.
Many applications have been reported for asymmetric
synthesis employing this enzyme (67–70).
Unlike pig pancreatic lipase, which is highly active
in organic media, PLE shows very low activity in or-
ganic solvents. Many factors, including water activity, the
nature of the organic solvents and the formulation of the
enzyme, affect the activity and enzyme stability in or-
ganic solvents. Immobilization on solid supports, cova-
lent binding of methoxypoly(ethylene glycol) (MPEG)
residues, lyophilisation by organic polymers, cross-link-
ing of enzyme crystals, sol-gel entrapment, and entrap-
ment in reverse micelles are the most important formu-
lations that usually improve the performance of this
enzyme in organic media (71–74).
A procedure has been developed for the highly
enantioselective enzyme-catalyzed resolution of the anti-
viral agent 2’,3’-dideoxy-5-fluoro-3’-thiacytidine (FTC,
Emtriva®) and related compounds, based on PLE medi-
ated hydrolysis of their butyrate ester derivatives (75).
PLE preferentially hydrolyzed the (+)-enantiomers and
the use of butyrate esters facilitated the separation of the
optically enriched, unreacted substrate from the medium
by an extraction with CHCl3. This process was success-
fully applied for the preparation of multi-gram quantities
of enantiomerically pure (–)-FTC, which had an excellent
activity/toxicity against HIV-1 (75) (Fig. 7). Emtriva® was
approved as an anti-HIV drug in 2003 (76).
Using commercially available pig liver esterase, en-
antioselective hydrolysis on a series of substituted -ami-
no acid phenolic esters was performed (77). (R)-amino
acid esters are novel compounds possessing hypnotic
activity. Attempting an asymmetric synthesis of (R)-en-
antiomers, the reactions of bis(2-methoxyethyl)amine
with -bromo intermediates were first carried out to
produce -amino acid phenolic esters followed by de-






























(2 ,3 )-epoxy-1-tridecanolR S
(2 ,3 )-epoxy-1-tridecanol-esterS R
rac-epoxy-1-tridecanol
Fig. 6. Synthesis of Disparlur® precursor based on kinetic resolution
-racemization. The active (R)-enantiomers were recover-
ed in 25–30 % yield (max. 50 %) and in greater than 99.5
% e.e. These reactions have been scaled up and have
been used to obtain multi-gram quantities of target com-
pounds (see Fig. 8) (77).
The PLE-catalyzed hydrolysis of racemic hydroxy-
tramadol derivatives (racemic -hydroxytramadol: poten-
tial analgesics) in aqueous buffer at pH=7.0 in the pres-
ence of 16 % acetone proceeded readily. It gave the alco-
hol with 93 % e.e. and 96 % yield and the ester with 72 %
e.e. and 99 % yield, respectively (the quoted yields are
based on one enantiomer) (67). An economical multi-mol
scale PLE-catalyzed resolution of -hydroxytramadol
butyrate ester can be achieved since the enzyme can be
stabilized by the addition of bovine serum albumin and
recovered by membrane filtration with only a minor loss
of activity after large-scale hydrolysis in water (67).
For the repetitive two phase hydrolysis of meso-di-
ester (dimethyl cis-cyclohex-4-ene-1,2-dicarboxylate) to the
corresponding monomethyl ester (monomethyl cis-cyclo-
hex-4-ene-1,2-dicarboxylate) by PLE on a multi-gram
scale (Fig. 9), the enzyme was stabilized against organic
solvents by immobilization in a polysulphone hollow fi-
bre ultrafiltration membrane reactor. The e.e. value of
monomethyl ester was still high (>97 %) and the enzyme
retained 62 % activity (68). A further PLE-catalyzed cen-
trosymmetric meso compound hydrolysis was reported
with 100 % conversion and an e.e. for the products higher
than 99.5 % (78).
Pig liver esterase was primarily used as a crude en-
zyme in powdered pig liver. Its application was limited
due to the variable fractions in the extracts, which dif-
fered from batch to batch, and the relatively expensive
enzyme source. However, it was demonstrated that PLE
is a versatile biocatalyst that converts a broad range of
compounds with a high stereoselectivity. A PLE gene
has been cloned recently (79,80) and highly over-ex-
pressed in the methylotrophic yeast Pichia pastoris (81).






































































Fig. 8. PLE catalyzed hydrolysis of substituted -amino acid phenolic esters (compound 1: R1=H, R2=Et; compound 2: R1=Me,
R2=Et; compound 3: R1=H, R2=nPr)
A recombinant PLE isoenzyme (rPLE) could be produc-
ed with reliable product quality without interference of
other isoenzymes and hydrolases, but it showed striking
differences in substrate specificity and enantioselectivity
compared to commercial enzymes from Fluka, Sigma or
Roche Diagnostics. This was especially seen for the ac-
tivity on naphthyl-butyrate (81) and the enantioselectivity
for the kinetic resolution of (R,S)-1-phenyl-2-propyl ace-
tate (82) and (R,S)-1-phenyl-2-butyl acetate (83) (Fig. 10).
Thus it must be emphasized that the expressed en-
zyme showed interesting features, but the name recom-
binant pig liver esterase (rPLE) is misleading since many
bioconversions employing this enzyme result in prod-
ucts other than those obtained with the commercial na-
tive enzyme preparations. Variants of the cloned este-
rase gene were obtained by site-directed mutagenesis
and the enantioselectivity was further increased. A six-
-fold increase in enantioselectivity compared to rPLE wild
type was observed in the hydrolysis of racemic phenyl-
ethyl acetate using a variant containing a single amino
acid change (E77G) (84).
Carboxypeptidase B and trypsin
Carboxypeptidase B preferentially hydrolyzes the
basic amino acids lysine, arginine and ornithine from the
C-terminal position of polypeptides. Trypsin is a pan-
creatic serine protease with a substrate specificity based
on positively charged lysine and arginine side chains.
The key source for these enzymes is pig pancreas. They
are mainly used in the process for the production of hu-
man insulin, which is a polypeptide hormone and used
as the therapeutic for the wide-spread disease diabetes
mellitus (85).
There are four main routes to produce insulin: extrac-
tion from human pancreas, chemical synthesis, conver-
sion of porcine insulin to human insulin and fermenta-
tive production by genetically engineered microorganisms.
The last of these was used by Eli Lilly, Hoechst Marion
Roussel and Novo Nordisk. Pig pancreas carboxypepti-
dase B and trypsin were involved in these processes
(59). At first, the proinsulin gene with an N-terminally
attached methionine was over-expressed intracellularly
as a fusion protein with the trpE gene in Escherichia coli.
Methionine is needed for the subsequent cleavage of the
fusion partner trpE. The proinsulin was formed after pu-
rification, cyanogen bromide (CNBr) cleavage of the fu-
sion protein and an oxidative sulfitolysis process. Then
proinsulin was cleaved by carboxypeptidase B from pig
pancreas to yield human insulin. The reaction was car-
ried out in aqueous medium at 30–35 °C with more than
95 % yield. For the trypsin method, the precursor proin-
sulin was directly produced in a fermentation process
employing recombinant Escherichia coli, this production
being subsequently followed by the enzymatic reaction.
The reaction conditions were different in this case (tem-
perature: 6 °C) and the yield was only >70 % (59,85).
Similar processes were also performed in Hoechst Ma-
rion Roussel: their carboxypeptidase process also started
with expression of a proinsulin fusion protein in Esche-
richia coli and the conversion and yield were >99.9 %
and >90 %, respectively, after 4–6 h of reaction in aque-
ous medium at 30–35 °C (reactor volume: 7500 L; capacity:
>0.5 t/year). In a different approach, the pre-proinsulin
gene was produced directly by cultivation of recombi-
nant E. coli, using the trypsin method. More than 99.9 %
conversion and >65 % yield were achieved after 6 h of
reaction time at 6 °C (reactor volume: 10 000 L; capacity:
>0.5 t/year). Novo Nordisk combined recombinant ex-
pression in yeast with trypsin conversion: proinsulin was
over-expressed in Saccharomyces cerevisiae and directly
converted to the threonin ester of insulin by transpepti-
dation with trypsin (batch reaction). To prevent the pos-
sible cleavage by trypsin at position 22 of chain B, low
water concentrations were maintained through the addi-
tion of organic solvents. A surplus of threonin ester, low
temperature (6 °C) and low pH (<7.0) were applied.
More than 99.9 % conversion and a yield greater than
97 % were obtained in this process and the threonin es-
ter formed could be converted into human insulin by
simple hydrolysis (86).
Production of Fine Chemicals with E.C. 4 –
Lyases
Hydroxynitrile lyase (HNL)
In many plants, the release of HCN from damaged
plant tissues is believed to serve as a defensive strategy
against herbivoral attack or as a nitrogen source for the
biosynthesis of L-asparagine. Hydroxynitrile lyases (HNLs,
MDLs) are responsible for these reactions and their pre-
ferred natural substrates, cyanohydrins, are separated
from the catalysts by compartmentalization on tissue or
subcellular level. In synthetic chemistry, HNLs are mainly
employed for the reverse reactions. Syntheses of optically











Fig. 9. PLE resolution of dimethyl cis-cyclohex-4-ene-1,2-dicar-
boxylate
OAcOH
( )-1-phenyl-2-butyl acetateR,S( )-1-phenyl-2-butyl alcoholS ( )-1-phenyl-2-butyl alcoholR
rPLE PLE (Fluka, Sigma)
OH
Fig. 10. Different enantioselectivity of recombinant PLE and commercially available PLE for the hydrolysis of (R,S)-1-phenyl-2-butyl
acetate
active cyanohydrins are carried out by selective enzy-
matic addition of (hydro)cyanide to carbonyl groups
(Fig. 11).
Cyanohydrins are important building blocks for syn-
theses of pharmaceuticals and agrochemicals such as
-hydroxy acids, -hydroxy ketones and -amino alco-
hols. HNLs are known from more than 2000 different
living sources and almost a dozen enzymes have been
purified and characterized from cyanogenic plants. The
main sources were Rosaceae (Prunus amygdalus, PaHNL),
Gramineae (Sorghum bicolor, SbHNL), Euphorbiaceae (He-
vea brasiliensis, HbHNL; Manihot esculenta, MeHNL) and
Linaceae (Linum usitatissimum, LuHNL) (87). Since 1996,
several HNL genes have been cloned and over-expres-
sed in Escherichia coli (88), Saccharomyces cerevisiae (89)
and Pichia pastoris (89,90), thereby making the large scale
production of (S)- and (R)-cyanohydrins by HNLs feasi-
ble.
SbHNL is (S)-selective and was the first (S)-HNL used
in organic solvents (where predominantly enzymatic re-
action takes place) for the preparation of (S)-cyanohyd-
rins such as (S)-p-hydroxymandelonitrile. Its major draw-
backs include limited availability and limited substrate
specificity: only aromatic and heteroaromatic aldehydes
are accepted, while aliphatic aldehydes or ketones are
not converted (91,92). In order to improve accessibility
and expand the substrate range for these types of reac-
tions, MeHNL from cassava and HbHNL from Hevea bra-
siliensis were investigated in detail. These two HNLs are
nowadays available in sufficient amounts for synthetic
processes due to successful over-expression in Escherichia
coli and Pichia pastoris, respectively. They are mainly used
for the production of (S)-m-phenoxybenzaldehyde cyano-
hydrin in a biphasic process (98 % yield, 99 % e.e.) by
DSM and Nippon Shokubai (93–95). This cyanohydrin is
an intermediate for the production of pyrethroids and is
produced in ton-scale at DSM (96) (Fig. 12).
The 3D-structures of HbHNL and MeHNL have
been determined (97,98) and provided the basis for sub-
strate specificity improvements by rational enzyme de-
sign. Docking simulations between HbHNL and chiral
cyanohydrins showed the presence of a catalytic triad
composed of a serine, a histidine and an aspartate resi-
due and indicated a general acid-base catalysis mecha-
nism (99). The active site seems to be accessible from the
surface only through a short channel. This narrow channel
is capped by a bulky tryptophan residue (W128), which
limits the substrate transport efficiency to the enzyme’s
active site. Thus, although HbHNL and MeHNL accept a
wide range of carbonyl compounds, they showed low
catalytic efficiency for the conversion of aldehydes with
bulky substituents. By replacing the tryptophan at posi-
tion 128 with smaller amino acids such as alanine or
glycine, large substrates can enter and bind to the active
center efficiently. This resulted in higher production and
shorter reaction time (100).
(R)-hydroxynitrile lyases are mainly used for synthe-
sis of (R)-mandelonitrile and its derivatives, which can
subsequently be hydrolyzed to their corresponding car-
boxylic acids. The resulting -hydroxy acids are used as
chiral building blocks for synthesis of active pharmaceu-
tical compounds and as racemate-resolving agents. There
are two main representative recombinant (R)-hydroxyni-
trile lyases: LuHNL and PaHNL. LuHNL has been cloned
and over-expressed in Pichia pastoris, but with aromatic
aldehydes the conversion to cyanohydrins could not be
done to completion with this recombinant HNL and the
enantioselectivity was low (101). PaHNL from almonds
is an excellent tool for the preparation of (R)-cyanohyd-
rins and it is also the first discovered (R)-HNL (87).
PaHNL can be isolated and purified from almond meal.
Aliphatic, aromatic and heterocyclic aldehydes as well
as ketones are good substrates for this enzyme (102,103).
For high enantioselectivity, especially for substrates that
are accepted less efficiently than mandelonitrile, cyano-
hydrin synthesis has to be performed at low pH-values
where the competitive chemical reaction is suppressed
and the enantiomerically pure cyanohydrins that are pro-
duced are stable. However, the enzyme from natural
sources is relatively expensive and lacks sufficient sta-
bility at low pH. In addition, enzyme preparations from
different batches and suppliers contain different propor-
tions of isoenzymes. This might be the main reason for
varying enantioselectivity and conversion rates observed
for the same substrate in different processes (104).
Recently at the Research Centre for Applied Biocata-
lysis, Graz, the PaHNL isoenzyme 5 gene has been cloned,
expressed and optimized successfully for industrial ap-





















Fig. 12. (S)-m-phenoxybenzaldehyde cyanohydrin synthesis by Hevea brasiliensis hydroxynitrile lyase (HbHNL) in a biphasic process
(iPr2O: isopropanol; MTBE: methyl tertiary butyl ether)
plications through a comprehensive molecular engineer-
ing process employing Pichia pastoris (8,90). It is note-
worthy that this recombinant PaHNL isoenzyme 5 shows
high stability even at pH-values lower than 3. When se-
cretion of over-expressed enzyme was driven by its na-
tive secretory signal sequence, 250 mg of active secreted
enzyme per litre of culture supernatant were obtained.
The recombinant enzyme showed extensive glycosyla-
tion and twice higher specific activity than the isolated
PaHNL from almond seeds. In a further step, the first
amino acid of the mature protein, leucine, was changed
into glutamine and the native plant signal sequence was
replaced by the alpha mating factor leading sequence
from Saccharomyces cerevisiae. In this manner, the enzyme
expression level was improved approximately 4-fold. A
production level of 1 g/L provides almost unlimited ac-
cess to this biocatalyst, which in nature is expressed in
floral tissues of almond trees (8,90). The recombinant
enzyme is used industrially on a ton-scale for several
processes at DSM.
Enzymatic synthesis of (R)-2-chlorobenzaldehyde
cyanohydrin is the key step in the synthesis of (R)-2-
chloromandelic acid, which is the chiral building block
for the synthesis of the antidepressant and platelet ag-
gregation inhibitor Clopidogrel® (105). This reaction was
carried out in microaqueous or biphasic systems. Native
PaHNL is employed for this process of Nippon Shoku-
bai and Clariant, resulting in an e.e. of greater than 83 %
(Fig. 13) (106–108).
The produced (R)-o-chloromandelonitrile can then be
converted into (R)-o-chloromandelic acid without race-
mization (1). However, ortho-substituted substrates were
converted with relatively low yield, low turnover frequen-
cies (TOF) and low e.e. values (109).
At DSM, a mutant of PaHNL5 is employed for the
production of (R)-2-chloromandelic acid. Based on the
structural information of the isoenzyme PaHNL1 (110),
as well as on docking experiments of chloro-substituted
benzaldehydes with a model of PaHNL5, the amino acid
residues which are in close contact with the substrate
were identified. Alanine 111 appeared to undergo steric
clashes with the chloro-substituent in the ortho-position.
Changing alanine at position 111 to glycine resulted in
improved enzymatic activity with 2-Cl-benzaldehyde and
can be used for the production of (R)-o-chloromandelic
acid with >95 % yield and >95 % e.e. (8).
The other lyases or C-C bond-forming enzymes (i.e.
other than HNLs) that are used in industrial applica-
tions currently originate exclusively from bacteria and
fungi (111).
Production of Fine Chemicals with E.C. 5 –
Isomerases
Epimerase
Epimerases are applied in industry to produce N-
acetylneuraminic acid (Neu5Ac) from N-acetyl-D-gluco-
samine (GlcNAc) and pyruvate with porcine kidney N-
acyl-D-glucosamine 2-epimerase (GlcNAc 2-epimerase)
and Escherichia coli N-acetylneuraminate lyase (Neu5Ac
lyase) (59). Neu5Ac has many biological functions as a
receptor, by masking receptors and by regulation of the
immune system (112). Due to these versatile functions, it
has been used for the production of different therapeu-
tics (113).
An integrated process was developed with porcine
kidney GlcNAc 2-epimerase and Escherichia coli Neu5Ac
lyase in a membrane reactor operated continuously at
pH=7.5. The shortcomings of this process are that the
epimerase was not available in large quantities and that
it requires ATP as an allosteric activator. Additionally,
both enzymes were inhibited by high concentrations of
Neu5Ac (114).
The porcine GlcNAc 2-epimerase (115) and Escherichia
coli Neu5Ac lyase (116) have been cloned and over-ex-
pressed in Escherichia coli to provide sufficient enzyme
for the large-scale production of Neu5Ac (117) and this
also promises to be applicable to the mass production of
sialic acid at low cost (118).
For the production of Neu5Ac, the enzymatic epi-
merization and aldol condensation proceeded in a rever-
sible process (Fig. 14). An excess molar amount of pyru-
vate was used to shift the equilibrium towards synthesis
of Neu5Ac. The original reaction mixture consisted of 27
kg of GlcNAc and 8 kg of pyruvate in 150 L of water be-
fore both enzymes were added. At the beginning, the
molar ratio of GlcNAc to pyruvate was only 1:0.6 to avoid
inhibition of GlcNAc 2-epimerase. The reaction was start-
ed by the addition of the two enzymes and continued
by the addition of pyruvate step-by-step. After 240 h,
the conversion of GlcNAc reached 77 % and 23 kg of
Neu5Ac were obtained. This process was applied for multi
kg production of Neu5Ac (Marukin Shoyu, Japan) (59).








Fig. 13. Synthesis of (R)-o-chloromandelonitrile via PaHNL (e.e.=

























Fig. 14. Enzymatic synthesis of Neu5Ac from GlcNAc and py-
ruvate
Conclusions and Perspectives
For a long time biocatalysis has been taken as a pro-
spective area for chemical synthesis, but the industrial
applications were moderate, especially for enzymes
from higher eukaryotes. Despite the fact that only a few
industrial applications of eukaryotic enzymes have been
reported, this review summarizes a significantly increas-
ing use of these catalysts in organic syntheses.
Simple and quick access to large enzyme quantities
was one of the major bottlenecks hampering industrial
applications. Due to recent progress in heterologous en-
zyme production, this problem is now largely solved.
Also the problem of heterogeneities in enzyme prepara-
tions has been solved by heterologous expression of sin-
gle isoenzymes. In addition, a variety of processes em-
ploying hydrolases and other enzymes from animal
sources have been reported, some of which were aimed
to be used for the production of active pharmaceutical
intermediates. However, there is still considerable skep-
ticism about the employment of enzymes from animal
resources due to the high risk of infectious contamina-
tions (especially prions). Therefore, the efficient cloning
and heterologous over-expression of these enzymes in
suitable (microbial) hosts can be regarded as seminal
progress in this field of biocatalysis.
The future will show if the discovery and enzyme
engineering processes can also be accelerated to make
higher eukaryotes ever more competitive as a source for
robust and efficient industrial enzymes.
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Enzimi vi{ih eukariota za industrijsku biokatalizu
Sa`etak
Industrijska proizvodnja finih kemikalija, sastojaka hrane, farmaceutskih proizvoda,
agrokemikalija i njihovih me|uprodukata temelji se na sve ve}oj primjeni biokatalize, tj.
na enzimima ili cijelim stanicama {to kataliziraju pretvorbu molekula. Jednostavni postupci
otkrivanja, kloniranja i pove}ane ekspresije, te brzi rast daju prednost fungima i kvascima,
a osobito bakterijama kao izvorima biokatalizatora. Vi{i eukarioti sadr`e skoro neogra-
ni~eni broj potencijalnih biokatalizatora. Danas je opskrba tim enzimima u industrijskim
procesima ograni~ena zbog velike heterogenosti enzimskih pripravaka i opasnosti od in-
fekcijskih primjesa. U pro{losti se samo nekoliko `ivotinjskih te biljnih enzima iz poljopri-
vrednih otpadaka koristilo u proizvodnji hrane. Uporaba ekspresiranih bakterijskih sojeva
ili nekonvencionalnih kvasaca za heterolo{ku proizvodnju djelotvornih eukariotskih enzi-
ma mo`e nadomjestiti njihov nedostatak i omogu}iti dovoljnu koli~inu homogenih enzim-
skih pripravaka za pouzdanu i ekonomski opravdanu primjenu u industrijskom mjerilu.
Idealni enzimski procesi nisu opasni za okoli{ te provode skoro 100 %-tnu pretvorbu naj-
~e{}e neprirodnih supstrata u ~iste proizvode. Najnovija dostignu}a pokazuju da su ispla-
tivi biokataliti~ki procesi u industrijskom mjerilu, koriste}i enzime iz vi{ih eukariota (bilja-
ka ili `ivotinja), kao i njihova primjena u pilot-postrojenjima.
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